Hologic, Inc. (HOLX) Receives Average Recommendation of “Buy” from Analysts
Hologic, Inc. (NASDAQ:HOLX) has been given a consensus rating of “Buy” by the fifteen brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $48.55.
A number of research firms have commented on HOLX. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $45.00 price objective (down from $50.00) on shares of Hologic in a research report on Wednesday, August 9th. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Jefferies Group LLC set a $49.00 target price on shares of Hologic and gave the company a “buy” rating in a research report on Sunday, May 28th. Barclays PLC reissued an “equal weight” rating and issued a $51.00 target price (down previously from $53.00) on shares of Hologic in a research report on Wednesday, August 9th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st.
Shares of Hologic (NASDAQ:HOLX) opened at 37.42 on Friday. The company’s 50-day moving average is $42.62 and its 200 day moving average is $42.82. The firm has a market capitalization of $10.50 billion, a price-to-earnings ratio of 13.94 and a beta of 0.90. Hologic has a 1-year low of $35.15 and a 1-year high of $46.80.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. During the same period in the previous year, the business posted $0.51 earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, analysts expect that Hologic will post $2.01 EPS for the current fiscal year.
In related news, Director Elaine Ullian sold 8,938 shares of the company’s stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $43.99, for a total transaction of $393,182.62. Following the completion of the sale, the director now owns 23,810 shares of the company’s stock, valued at $1,047,401.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter J. Valenti III sold 10,005 shares of the company’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total transaction of $434,617.20. Following the sale, the insider now directly owns 20,994 shares of the company’s stock, valued at approximately $911,979.36. The disclosure for this sale can be found here. Insiders have sold 51,551 shares of company stock valued at $2,244,458 in the last ninety days. 0.79% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of HOLX. Commonwealth Bank of Australia boosted its stake in Hologic by 31.0% in the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 600 shares in the last quarter. TrimTabs Asset Management LLC boosted its stake in Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 1,408 shares in the last quarter. Advisor Partners LLC purchased a new stake in Hologic during the first quarter valued at $201,000. National Asset Management Inc. purchased a new stake in Hologic during the second quarter valued at $203,000. Finally, Miles Capital Inc. purchased a new stake in Hologic during the first quarter valued at $206,000. 94.43% of the stock is owned by institutional investors and hedge funds.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.